Status:
TERMINATED
Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg
Lead Sponsor:
Mylan Pharmaceuticals Inc
Conditions:
Healthy
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The objective of this study was to investigate the bioequivalence of Mylan olanzapine 20 mg tablets to Eli Lilly Zyprexa® 20 mg tablets following a single, oral 20 mg (1 x 20 mg) dose administration u...
Eligibility Criteria
Inclusion
- healthy, adult subjects, 18 years and older
- able to swallow medication
Exclusion
- institutionalized subjects
- history of any significant disease
- use of any prescription or OTC medications within 14 days of start of study
- received any investigational products within 30 days prior to start of study
Key Trial Info
Start Date :
May 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00647972
Start Date
May 1 2003
Last Update
April 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kendle International Inc.
Morgantown, West Virginia, United States, 26505